Garvey, W. Timothy

Once-Weekly Semaglutide 7·2 Mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial

Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 119

Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps

Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Risk Factors

Cited by 113

New horizons. A new paradigm for treating to target with second-generation obesity medications

Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 110

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

Verma, S., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Jensen, C., Kandler, K., Kushner, R. F., Rubino, D. M., & Kosiborod, M. N. (2023) · eClinicalMedicine

Adipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

Cited by 106

Diet, Insulin Resistance, and Obesity: Zoning in on Data for Atkins Dieters Living in South Beach

Lara-Castro, C., & Garvey, W. T. (2004) · The Journal of Clinical Endocrinology & Metabolism

Diet and metabolism studiesDietary Effects on Health

Cited by 106

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 97

American Association of Clinical Endocrinology Consensus Statement: Addressing Stigma and Bias in the Diagnosis and Management of Patients with Obesity/Adiposity-Based Chronic Disease and Assessing Bias and Stigmatization as Determinants of Disease Severity

Nadolsky, K., Addison, B., Agarwal, M., Almandoz, J. P., Bird, M. D., DeGeeter Chaplin, M., Garvey, W. T., & Kyle, T. K. (2023) · Endocrine Practice

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 86

Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects

Lara-Castro, C., Newcomer, B. R., Rowell, J., Wallace, P., Shaughnessy, S. M., Munoz, A. J., Shiflett, A. M., Rigsby, D. Y., Lawrence, J. C., Bohning, D. E., et al. (2008) · Metabolism

Diet and metabolism studiesDietary Effects on Health

Cited by 82

Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes

Hill, H., Grams, J., Walton, R., Liu, J., Moellering, D., & Garvey, W. (2014) · Hormone and Metabolic Research

Adipokines, Inflammation, and Metabolic DiseasesBone Metabolism and Diseases

Cited by 80

Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans

Willi, S. M., Kennedy, A., Wallace, P., Ganaway, E., Rogers, N. L., & Garvey, W. T. (2002) · Diabetes

Peroxisome Proliferator-Activated ReceptorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 77

Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies

Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 72

Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications

Garvey, W. T. (2022) · Endocrine Practice

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 66

New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)

Henry, R. R., Chilton, R., & Garvey, W. T. (2013) · Journal of Diabetes and its Complications

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 53

Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study

Wilkinson, L., Yi, N., Mehta, T., Judd, S., & Garvey, W. T. (2020) · PLOS Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsStatistical Methods in Epidemiology

Cited by 47

Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes

Guo, F., & Garvey, W. T. (2015) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 44

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial

Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 44

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

Cardiometabolic disease staging predicts effectiveness of weight-loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine/topiramate extended release

Guo, F., & Garvey, W. T. (2017) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 37

Pharmacotherapy for weight management in the VHA

Semla, T. P., Ruser, C., Good, C. B., Yanovski, S. Z., Ames, D., Copeland, L. A., Billington, C., Ferguson, U. I., Aronne, L. J., Wadden, T. A., et al. (2017) · Journal of General Internal Medicine

Pharmacology and Obesity TreatmentObesity and Health Practices

Cited by 28

Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity

Wilkinson, L., Holst‐Hansen, T., Laursen, P. N., Rinnov, A. R., Batterham, R. L., & Garvey, W. T. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 25

Childhood maltreatment is an independent risk factor for prediabetic disturbances in glucose regulation

Li, L., Garvey, W. T., & Gower, B. A. (2017) · Frontiers in Endocrinology

Child Abuse and TraumaDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 21

KSRP is critical in governing hepatic lipid metabolism through controlling Per2 expression

Chou, C.-F., Zhu, X., Lin, Y.-Y., Gamble, K. L., Garvey, W. T., & Chen, C.-Y. (2015) · Journal of Lipid Research

Circadian rhythm and melatoninLiver Disease Diagnosis and Treatment

Cited by 20

Examining the evidence for weight management in individuals with type 2 diabetes

Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 18

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT ‐1 trial

Hankosky, E. R., Lebrec, J., Lee, C. J., Dimitriadis, G. K., Jouravskaya, I., Stefanski, A., & Garvey, W. T. (2025) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 17